Cancer immunotherapy side effect study pulled before it began
NCT ID NCT06521762
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test whether the drug etrasimod (VELSIPITY) could help reduce the need for steroids in cancer patients who develop diarrhea and colon inflammation from immune checkpoint inhibitors. It planned to enroll about 0 participants with advanced cancer who had moderate to severe symptoms. However, the trial was withdrawn before any patients were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Etrasimod (also called VELSIPITY) taken as a 2 mg oral tablet daily, plus corticosteroids
- What this could lead to
- If it had worked, this could have pointed toward a way to reduce steroid use and shorten treatment breaks for cancer patients with severe diarrhea and colitis caused by immunotherapy.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. It was a small early-stage study, and the approach may not have proven better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-RELATED DIARRHEA AND COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States